A pilot study of preoperative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early-stage/resectable breast cancer (ESBC).

Authors:

Abstract
1098 Background: Because intratumoral cryo with immune modulation generates a potent systemic anti-tumor immune response in murine models, this strategy may improve outcomes for women with ESBC. In this study, we evaluated the safety of pre-op cryo and/or ipi (10mg/kg) in ESBC pts and explored immune correlates including tumor infiltrating lymphocytes (TILs). Methods: Eligibility: age ≥18y with operable ≥1.5 cm invasive ESBC planning mastectomy (TM). Pts were sequentially assigned to receive pre-op: cryo alone (group A), ipi alone (B), or ipi and cryo (C). Tissue biopsies and/or cryo were performed 7-10d prior to TM. Ipi was administered 8-15d prior to TM (1-5d prior to cryo). The regimen was to be considered safe/tolerable if at least 5/6 pts in each group proceed to TM without delay. Toxicity evaluation continued for 30d after TM for group A and 12wks after ipi administration for groups B&C. Research peripheral bloods for immune correlates were obtained at baseline, biopsy, TM and 2-3 wks thereafter. Blood, biopsy and TM samples were evaluated by flow-cytometry. Results: The study is complete. Pre-op cryo-alone, ipi-alone and the combination were well tolerated and the primary safety endpoint was achieved with all 19 enrolled pts undergoing TM without delay. Group A was expanded to 7 pts after a possible technical failure in 1 pt, 6 pts enrolled to group B and 6 pts enrolled to group C. Median age was 48y (range 34-72y). Tumor necrosis/infarction was observed in 9/12 pts who underwent cryo. A trend toward an increased frequency of blood CD4+ICOS+, CD8+ICOS+, CD4+Ki67+ and CD8+Ki67+ T-cells was observed at TM compared with baseline in the ipi treated groups only. Analysis of TILs in the TM specimens suggested a higher ratio of CD8+Ki67+ T-cells to CD4+CD25+FOXP3+ (T-regulatory) cells in group C when compared with A&B. Conclusions: Pre-op cryo and ipi, alone or in combination, are safe/tolerable in pts with ESBC. Immune correlates revealed activation of T-cells in the blood in single-dose ipi treated pts and a modest increase in the ratio of tumor CD8+Ki67+ T-cells to T-regulatory cells after combination therapy only. A Phase II study of pre-op ipi and cryo in ESBC is planned. Clinical trial information: NCT01502592.